185 related articles for article (PubMed ID: 9219272)
1. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV.
Drucker DJ; Shi Q; Crivici A; Sumner-Smith M; Tavares W; Hill M; DeForest L; Cooper S; Brubaker PL
Nat Biotechnol; 1997 Jul; 15(7):673-7. PubMed ID: 9219272
[TBL] [Abstract][Full Text] [Related]
2. mRNA levels of dipeptidyl peptidase IV decrease during intestinal adaptation.
Dunphy JL; Justice FA; Taylor RG; Fuller PJ
J Surg Res; 1999 Nov; 87(1):130-3. PubMed ID: 10527714
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
Lugari R; Dei Cas A; Ugolotti D; Barilli AL; Camellini C; Ganzerla GC; Luciani A; Salerni B; Mittenperger F; Nodari S; Gnudi A; Zandomeneghi R
Horm Metab Res; 2004 Feb; 36(2):111-5. PubMed ID: 15002062
[TBL] [Abstract][Full Text] [Related]
4. The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight.
Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Saeki T; Tanaka I
Eur J Pharmacol; 2004 Mar; 488(1-3):213-8. PubMed ID: 15044053
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice.
Hartmann B; Thulesen J; Kissow H; Thulesen S; Orskov C; Ropke C; Poulsen SS; Holst JJ
Endocrinology; 2000 Nov; 141(11):4013-20. PubMed ID: 11089531
[TBL] [Abstract][Full Text] [Related]
6. A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres.
Gao Z; Tang Y; Chen J; Bai R; Zhang Q; Hou Y; Lu Y; Bai G
Peptides; 2009 Oct; 30(10):1874-81. PubMed ID: 19647775
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of glucagon-like peptide-2 in pigs: role of dipeptidyl peptidase IV.
Hansen L; Hare KJ; Hartmann B; Deacon CF; Ugleholdt RK; Plamboeck A; Holst JJ
Regul Pept; 2007 Feb; 138(2-3):126-32. PubMed ID: 17107718
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome.
Martin GR; Wallace LE; Sigalet DL
Am J Physiol Gastrointest Liver Physiol; 2004 Jun; 286(6):G964-72. PubMed ID: 14962847
[TBL] [Abstract][Full Text] [Related]
10. Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors.
Longenecker KL; Stewart KD; Madar DJ; Jakob CG; Fry EH; Wilk S; Lin CW; Ballaron SJ; Stashko MA; Lubben TH; Yong H; Pireh D; Pei Z; Basha F; Wiedeman PE; von Geldern TW; Trevillyan JM; Stoll VS
Biochemistry; 2006 Jun; 45(24):7474-82. PubMed ID: 16768443
[TBL] [Abstract][Full Text] [Related]
11. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
Otto Buczkowska E; Dworzecki T
Przegl Lek; 2004; 61(9):947-50. PubMed ID: 15803906
[TBL] [Abstract][Full Text] [Related]
12. Circulation and degradation of GIP and GLP-1.
Deacon CF
Horm Metab Res; 2004; 36(11-12):761-5. PubMed ID: 15655705
[TBL] [Abstract][Full Text] [Related]
13. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice.
Dubé PE; Forse CL; Bahrami J; Brubaker PL
Gastroenterology; 2006 Aug; 131(2):589-605. PubMed ID: 16890611
[TBL] [Abstract][Full Text] [Related]
14. Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward?
Yazbeck R; Howarth GS; Abbott CA
Cytokine Growth Factor Rev; 2009 Apr; 20(2):175-84. PubMed ID: 19324585
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.
Idris I; Donnelly R
Diabetes Obes Metab; 2007 Mar; 9(2):153-65. PubMed ID: 17300591
[TBL] [Abstract][Full Text] [Related]
16. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.
Hinke SA; Kühn-Wache K; Hoffmann T; Pederson RA; McIntosh CH; Demuth HU
Biochem Biophys Res Commun; 2002 Mar; 291(5):1302-8. PubMed ID: 11883961
[TBL] [Abstract][Full Text] [Related]
17. Chemoenzymatic synthesis of glycosylated glucagon-like peptide 1: effect of glycosylation on proteolytic resistance and in vivo blood glucose-lowering activity.
Ueda T; Tomita K; Notsu Y; Ito T; Fumoto M; Takakura T; Nagatome H; Takimoto A; Mihara S; Togame H; Kawamoto K; Iwasaki T; Asakura K; Oshima T; Hanasaki K; Nishimura S; Kondo H
J Am Chem Soc; 2009 May; 131(17):6237-45. PubMed ID: 19361194
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
19. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
Kieffer TJ; McIntosh CH; Pederson RA
Endocrinology; 1995 Aug; 136(8):3585-96. PubMed ID: 7628397
[TBL] [Abstract][Full Text] [Related]
20. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments.
Lenhard JM; Croom DK; Minnick DT
Biochem Biophys Res Commun; 2004 Nov; 324(1):92-7. PubMed ID: 15464987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
